|
|
Volumn 374, Issue 17, 2016, Pages 1688-1689
|
|
DRS. Feld and Zeuzem reply
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
SOFOSBUVIR PLUS VELPATASVIR;
ANTIVIRUS AGENT;
CARBAMIC ACID DERIVATIVE;
FUSED HETEROCYCLIC RINGS;
SOFOSBUVIR;
CLINICAL TRIAL (TOPIC);
DRUG RESPONSE;
HEPATITIS C;
HEPATITIS C VIRUS GENOTYPE 1;
HEPATITIS C VIRUS GENOTYPE 2;
HEPATITIS C VIRUS GENOTYPE 4;
HEPATITIS C VIRUS GENOTYPE 5;
HEPATITIS C VIRUS GENOTYPE 6;
HUMAN;
LETTER;
LIVER CIRRHOSIS;
PRIORITY JOURNAL;
RELAPSE;
SUSTAINED VIROLOGIC RESPONSE;
TREATMENT DURATION;
FEMALE;
GENETICS;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
MALE;
ANTIVIRAL AGENTS;
CARBAMATES;
FEMALE;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS;
HUMANS;
MALE;
SOFOSBUVIR;
|
|
EID: 84964933140
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1601160 Document Type: Letter |
|
Times cited : (8)
|
|
References (0)
|
